Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | TCF4 | P15884 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 5/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | TOP1 | P11387 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RHEB | Q15382 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19994537 | 0.90 | SIRT2 (0.69) | SIRT2SIRT1HDAC6TCF4CTNNB1 | |
| SCHEMBL1663678 | 0.88 | SIRT2 (0.58) | SIRT2SIRT1TCF4CTNNB1AURKA | |
| SCHEMBL15223904 | 0.88 | SIRT2 (0.58) | SIRT2SIRT1TCF4CTNNB1AURKA | |
| SCHEMBL20001676 | 0.87 | CHEK2 (0.64) | SIRT2SIRT1CHEK2PARP1 | |
| SCHEMBL19994533 | 0.86 | PKN1 (0.55) | HDAC6CHEK2KDM4ENPC1RAB9A | |
| SCHEMBL12392425 | 0.85 | SIRT2 (0.55) | SIRT2SIRT1HDAC6TCF4CTNNB1 | |
| SCHEMBL23845415 | 0.83 | HPSE (0.61) | SIRT2SIRT1KDM4ENPC1RAB9A | |
| SCHEMBL29698973 | 0.83 | HPSE (0.61) | SIRT2SIRT1KDM4ENPC1RAB9A | |
| SCHEMBL29002248 | 0.83 | SIRT2 (0.53) | SIRT2SIRT1TCF4CTNNB1AURKA | |
| SCHEMBL8770559 | 0.83 | HPSE (0.61) | SIRT2SIRT1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | TMBIM6, BAX, MAPK14 | SIRT2 1954/4885SIRT1 2241/4885HDAC6 200/4885 |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | TMBIM6, BAX, MAPK14 | SIRT2 1954/4885SIRT1 2241/4885HDAC6 200/4885 |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | TMBIM6, BAX, BCL2 | SIRT2 1990/4885SIRT1 2253/4885HDAC6 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.